Literature DB >> 94385

Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol.

P A van Zwieten, P B Timmermans.   

Abstract

Atenolol and metoprolol are beta 1-selective adrenergic receptor blockers, devoid of local anesthetic and intrinsic sympathomimetic properties. Their antihypertensive and hypotensive activities are equivalent. They differ with respect to their lipophilic character, as is apparent from their octanol/buffer (pH, 7.4 at 37 degrees C) partition coefficients: metoprolol, 1.084; atenolol, 0.012. We compared the two agents with regard to their acute hemodynamic effects and degree of penetration into the cerebrospinal fluid (CSF) and into the brain. For this purpose [3H]-metoprolol and [14C]-atenolol were injected either intravenously or into the left vertebral artery of chloralose-anesthetized cats. With both routes of administration, metoprolol, the more lipophilic of the two compounds, achieved much higher concentrations in the CSF and in the pontomedullary region than did atenolol. One hour after completion of an intravenous injection, the concentration of metoprolol in the CSF was about 6.5 times higher than that of atenolol; after administration into the vertebral artery, the difference was about ninefold. In spite of these considerable differences, the hypotensive and bradycardic activities of both drugs, administered intravenously or into the left vertebral artery, were virtually the same. These results suggest that the acute hemodynamic effects of metoprolol and atenolol are probably not due to an action within the central nervous system, but rather to a peripheral mechanism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94385     DOI: 10.1097/00005344-197901000-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 2.  Pharmacology of centrally acting hypotensive drugs.

Authors:  P A van Zwieten
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

3.  Brain levels and acute antihypertensive activity of beta-blockers.

Authors:  P A van Zwieten; P B Timmermans
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.

Authors:  A Westerlund
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

6.  The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment.

Authors:  B Abila; J F Wilson; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

7.  Beta-blocker brain concentrations in man.

Authors:  J M Cruickshank; G Neil-Dwyer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Cardiovascular and phrenic nerve responses to stimulation of the amygdala central nucleus in the anaesthetized rabbit.

Authors:  G E Cox; D Jordan; J F Paton; K M Spyer; L M Wood
Journal:  J Physiol       Date:  1987-08       Impact factor: 5.182

9.  Neurocardiology shows that the central, not peripheral, action of propranolol reduces mortality following acute coronary artery occlusion in the conscious pig.

Authors:  J E Skinner
Journal:  Integr Physiol Behav Sci       Date:  1991 Apr-Jun

Review 10.  Clinical pharmacokinetics of atenolol--a review.

Authors:  W Kirch; K G Görg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.